30 nov 2017 ano - FDA approved Sublocade, the first once-monthly injectable buprenorphine product for the treatment of moderate-to-severe opioid use disorder in adult patients who have initiated treatment with a transmucosal (absorbed through mucus membrane) buprenorphine- containing product. It is indicated for patients that have been on a stable dose of buprenorphine treatment for a minimum of seven days.

Adicionado na linha do tempo:

Opioids and the FDA

ByAnastasia

13 nov 2018

0

0

520

Data: